{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T04:19:35Z","timestamp":1648613975781},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1007\/s11883-006-0061-5","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T07:54:04Z","timestamp":1181030044000},"page":"26-31","source":"Crossref","is-referenced-by-count":1,"title":["Other than potency, are all statins the same?"],"prefix":"10.1007","volume":"8","author":[{"given":"Nicola","family":"Abate","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Chandalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"61_CR1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301\u20131307.","journal-title":"N Engl J Med"},{"key":"61_CR2","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","volume":"344","author":"PM Ridker","year":"2001","unstructured":"Ridker PM, Rifai N, Clearfield M, et al.: Air Force\/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959\u20131965.","journal-title":"N Engl J Med"},{"key":"61_CR3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","volume":"98","author":"PM Ridker","year":"1998","unstructured":"Ridker PM, Rifai N, Pfeffer MA, et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998, 98:839\u2013844.","journal-title":"Circulation"},{"key":"61_CR4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, et al.: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20\u201328.","journal-title":"N Engl J Med"},{"key":"61_CR5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","volume":"352","author":"SE Nissen","year":"2005","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29\u201338.","journal-title":"N Engl J Med"},{"key":"61_CR6","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/01.CIR.0000086460.55494.AF","volume":"108","author":"R Kleemann","year":"2003","unstructured":"Kleemann R, Princen HM, Emeis JJ, et al.: Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiin-flammatory effects of rosuvastatin. Circulation 2003, 108:1368\u20131374.","journal-title":"Circulation"},{"key":"61_CR7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00041552-200501000-00006","volume":"14","author":"SK Venugopal","year":"2005","unstructured":"Venugopal SK, Devaraj S, Jialal I: Related effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005, 14:33\u201337.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"61_CR8","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-139-8-200310210-00011","volume":"139","author":"EM Balk","year":"2003","unstructured":"Balk EM, Lau J, Goudas LC, et al.: Effects of statins on non-lipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003, 139:670\u2013682.","journal-title":"Ann Intern Med"},{"key":"61_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-0037-1612902","volume":"85","author":"C Joukhadar","year":"2001","unstructured":"Joukhadar C, Klein N, Prinz M, et al.: Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001, 85:47\u201351.","journal-title":"Thromb Haemost"},{"key":"61_CR10","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.103.15.1933","volume":"103","author":"I Jialal","year":"2001","unstructured":"Jialal I, Stein D, Balis D, et al.: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitivity C-reactive protein levels. Circulation 2001, 103:1933\u20131935.","journal-title":"Circulation"},{"key":"61_CR11","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.0000034508.55617.65","volume":"106","author":"AJ Taylor","year":"2002","unstructured":"Taylor AJ, Kent SM, Flaherty PJ, et al.: ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002, 106:2055\u20132060.","journal-title":"Circulation"},{"key":"61_CR12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0021-9150(02)00280-0","volume":"165","author":"S Wissen Van","year":"2002","unstructured":"Van Wissen S, Trip MD, Smilde TJ, et al.: Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002, 165:361\u2013366.","journal-title":"Atherosclerosis"},{"key":"61_CR13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1365-2796.2002.00966.x","volume":"251","author":"O Wiklund","year":"2002","unstructured":"Wiklund O, Mattsson-Hulten L, Hurt-Camejo E, Oscarsson J: Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 2002, 251:338\u2013347.","journal-title":"J Intern Med"},{"key":"61_CR14","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1161\/01.CIR.95.5.1126","volume":"95","author":"G O\u2019Driscoll","year":"1997","unstructured":"O\u2019Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126\u20131131.","journal-title":"Circulation"},{"key":"61_CR15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM199502233320801","volume":"332","author":"CB Treasure","year":"1995","unstructured":"Treasure CB, Klein JL, Weintraub WS, et al.: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995, 332:481\u2013487.","journal-title":"N Engl J Med"},{"key":"61_CR16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0002-9149(02)02602-4","volume":"90","author":"G Mercuro","year":"2002","unstructured":"Mercuro G, Zoncu S, Saiu F, et al.: Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels. Am J Cardiol 2002, 90:747\u2013750.","journal-title":"Am J Cardiol"},{"key":"61_CR17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/01.RES.0000134628.96682.9b","volume":"95","author":"JA Beckman","year":"2004","unstructured":"Beckman JA, Liao JK, Hurley S, et al.: Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 2004, 95:217\u2013223.","journal-title":"Circ Res"},{"key":"61_CR18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2362.1993.tb00776.x","volume":"23","author":"HA Kleinveld","year":"1993","unstructured":"Kleinveld HA, Demacker PN, De Haan AF, Stalenhoef AF: Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest 1993, 23:289\u2013295.","journal-title":"Eur J Clin Invest"},{"key":"61_CR19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF01696223","volume":"64","author":"J Mayer","year":"1992","unstructured":"Mayer J, Eller T, Brauer P, et al.: Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992, 64:196\u2013201.","journal-title":"Ann Hematol"},{"key":"61_CR20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/j.1552-4604.1991.tb03729.x","volume":"31","author":"Y Beigel","year":"1991","unstructured":"Beigel Y, Fuchs J, Snir M, et al.: Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol 1991, 31:512\u2013517.","journal-title":"J Clin Pharmacol"},{"key":"61_CR21","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1001\/jama.279.20.1643","volume":"279","author":"RS Rosenson","year":"1998","unstructured":"Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998, 279:1643\u20131650.","journal-title":"JAMA"},{"key":"61_CR22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.metabol.2004.12.012","volume":"54","author":"A Saklamaz","year":"2005","unstructured":"Saklamaz A, Comlekci A, Temiz A, et al.: The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Metabolism 2005, 54:677\u2013681.","journal-title":"Metabolism"},{"key":"61_CR23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0049-3848(02)00034-8","volume":"105","author":"I Seljeflot","year":"2002","unstructured":"Seljeflot I, Tonstad S, Hjermann I, Arnesen H: Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res 2002, 105:285\u2013290.","journal-title":"Thromb Res"},{"key":"61_CR24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/01.ATV.15.2.247","volume":"15","author":"A Notarbartolo","year":"1995","unstructured":"Notarbartolo A, Davi G, Averna M, et al.: Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995, 15:247\u2013251.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"61_CR25","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1161\/01.CIR.92.11.3172","volume":"11","author":"L Lacoste","year":"1995","unstructured":"Lacoste L, Lam JY, Hung J, et al.: Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995, 11:3172\u20133177.","journal-title":"Circulation"},{"key":"61_CR26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199509073331003","volume":"333","author":"JA Kobashigawa","year":"1995","unstructured":"Kobashigawa JA, Katznelson S, Laks H, et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621\u2013627.","journal-title":"N Engl J Med"},{"key":"61_CR27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00059-005-2685-6","volume":"5","author":"K Wenke","year":"2005","unstructured":"Wenke K, Meiser B, Thiery J, Reichart B: Impact of simvastatin therapy after heart transplantation: an 11-year prospective evaluation. Herz 2005, 5:431\u2013432.","journal-title":"Herz"},{"key":"61_CR28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","volume":"103","author":"DJ Freeman","year":"2001","unstructured":"Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357\u2013362.","journal-title":"Circulation"},{"key":"61_CR29","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1046\/j.1600-6143.2004.00598.x","volume":"4","author":"GV Prasad","year":"2004","unstructured":"Prasad GV, Kim SJ, Huang M, et al.: Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins). Am J Transplant 2004, 4:1897\u20131903.","journal-title":"Am J Transplant"},{"key":"61_CR30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.biopha.2004.09.005","volume":"58","author":"F Guclu","year":"2004","unstructured":"Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C: Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 2004, 58:614\u2013618.","journal-title":"Biomed Pharmacother"},{"key":"61_CR31","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jacc.2004.04.050","volume":"44","author":"Y Yu","year":"2004","unstructured":"Yu Y, Ohmori K, Chen Y, et al.: Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004, 44:904\u2013913.","journal-title":"J Am Coll Cardiol"},{"key":"61_CR32","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahlof B, Poulter NR, et al., for the ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149\u20131158.","journal-title":"Lancet"},{"key":"61_CR33","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.0000112604.74713.35","volume":"109","author":"MS Sabatine","year":"2004","unstructured":"Sabatine MS, Morrow DA, Giugliano RP, et al.: Implications of upstream glycoprotein IIb\/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina\/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation 2004, 109:874\u2013880.","journal-title":"Circulation"},{"key":"61_CR34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1081\/ERC-120025034","volume":"29","author":"H Altunbas","year":"2003","unstructured":"Altunbas H, Balci MK, Karayalcin U: No effect of simvastatin treatment on insulin sensitivity in patients with primary hypercholesterolemia. Endocr Res 2003, 29:265\u2013275.","journal-title":"Endocr Res"},{"key":"61_CR35","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1464-5491.1999.00113.x","volume":"16","author":"CM Hwu","year":"1999","unstructured":"Hwu CM, Kwok CF, Chen HS, et al.: Lack of effect of simvastatin on insulin sensitivity in Type 2 diabetic patients with hypercholesterolaemia: results from a double-blind, randomized, placebo-controlled crossover study. Diabet Med 1999, 16:749\u2013754.","journal-title":"Diabet Med"},{"key":"61_CR36","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)03155-X","volume":"356","author":"H Jick","year":"2000","unstructured":"Jick H, Zornberg GL, Jick SS, et al.: Statins and the risk of dementia. Lancet 2000, 356:1627\u20131631.","journal-title":"Lancet"},{"issue":"1\u20132","key":"61_CR37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000073981","volume":"23","author":"E Zamrini","year":"2004","unstructured":"Zamrini E, McGwin G, Roseman JM: Association between statin use and Alzheimer\u2019s disease. Neuroepidemiology 2004, 23(1\u20132):94\u201398.","journal-title":"Neuroepidemiology"},{"key":"61_CR38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archpsyc.62.2.217","volume":"62","author":"PP Zandi","year":"2005","unstructured":"Zandi PP, Sparks DL, Khachaturian AS, et al.: Cache County Study investigators. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005, 62:217\u2013224.","journal-title":"Arch Gen Psychiatry"},{"key":"61_CR39","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/archneur.62.7.1047","volume":"62","author":"TD Rea","year":"2005","unstructured":"Rea TD, Breitner JC, Psaty BM, et al.: Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005, 62:1047\u20131051.","journal-title":"Arch Neurol"},{"key":"61_CR40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1997.tb00971.x","volume":"45","author":"NC Santanello","year":"1997","unstructured":"Santanello NC, Barber BL, Applegate WB, et al.: Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc 1997, 45:8\u201314.","journal-title":"J Am Geriatr Soc"},{"key":"61_CR41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(02)09328-5","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group: MRC\/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:23\u201333.","journal-title":"Lancet"},{"key":"61_CR42","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, et al.: PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623\u20131630.","journal-title":"Lancet"},{"key":"61_CR43","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archneur.62.5.753","volume":"62","author":"DL Sparks","year":"2005","unstructured":"Sparks DL, Sabbagh MN, Connor DJ, et al.: Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005, 62:753\u2013757.","journal-title":"Arch Neurol"},{"key":"61_CR44","doi-asserted-by":"crossref","first-page":"23K","DOI":"10.1016\/S0002-9149(03)00779-3","volume":"92","author":"HB Brewer Jr","year":"2003","unstructured":"Brewer HB Jr: Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003, 92:23K-29K.","journal-title":"Am J Cardiol"},{"key":"61_CR45","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1097\/01.ASN.0000136778.32499.05","volume":"15","author":"A Verhulst","year":"2004","unstructured":"Verhulst A, D\u2019Haese PC, De Broe ME: Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004, 15:2249\u20132257.","journal-title":"J Am Soc Nephrol"},{"key":"61_CR46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.ajkd.2004.08.040","volume":"45","author":"M Epstein","year":"2005","unstructured":"Epstein M, Campese VM: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 2005, 45:2\u201314.","journal-title":"Am J Kidney Dis"},{"key":"61_CR47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000077704","volume":"102","author":"DG Vidt","year":"2004","unstructured":"Vidt DG, Cressman MD, Harris S, et al.: Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004, 102:52\u201360.","journal-title":"Cardiology"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-006-0061-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-006-0061-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-006-0061-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:35:30Z","timestamp":1559417730000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-006-0061-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["61"],"URL":"https:\/\/doi.org\/10.1007\/s11883-006-0061-5","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}